New combo therapy aims to fight rare nasal cancer before surgery
NCT ID NCT07614828
First seen Jun 04, 2026 · Last updated Jun 19, 2026 · Updated 3 times
Summary
This phase 2 trial is testing whether giving immunotherapy (Toripalimab) and chemotherapy (Temozolomide) before surgery can improve outcomes for people with a rare type of melanoma in the nasal cavity. The study will enroll 25 participants with resectable tumors. The main goal is to see if this approach can delay or prevent the cancer from spreading to other parts of the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUCOSAL MELANOMA OF THE HEAD AND NECK are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Eye & ENT Hospital
RECRUITINGShanghai, Shanghai Municipality, 200030, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Toripalimab (immunotherapy) and Temozolomide (chemotherapy)
What this could lead to
If successful, this approach could improve survival and reduce cancer spread in people with a rare and aggressive nasal melanoma.
What could go wrong
This is a small, early-phase trial with only 25 participants, so results may not apply broadly. The combination of treatments may cause significant side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.